Multicenter phase II trial of adjuvant S-1 plus Docetaxel for 6 months in patients with pathological stage III gastric cancer (OGSG1002)

A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group ：OGSG1203 (HERBIS-5)

A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group ：OGSG1203 (HERBIS-5)　

切除可能進行食道癌にたいする術前ACF vs DCF併用化学療法のランダム化比較試験：（OGSG1003）

IRI+Tmab併用療法の進行・再発HER2陽性胃癌既治療例に対する多施設第II相試験：OGSG1203 (HERBIS-5)

FU, IRI, OX不応KRAS野生型mCRCに対するIRI+Panitumumab 療法の日本人データ (OGSG1001)

自主的地域型臨床試験グループOGSGの実績と将来展望

Randomized phase II study of docetaxel vs Paclitaxel for patients with advanced or recurrent esophageal cancer who previously received fluoropyrimidine and platinum-based chemotherapy (OGSG1201)

Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus platinum (OGSG0701)

Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus CDDP（OGSG0701）